Recent findings of FIGHT-101 [75] using pemigatinib shows that the most frequent alterations co-occurring with FGFR amplifications were TP53 alterations, however genomic analysis of MCL patients (n = 162) did not show any FGFR1 activating mutations. This evidence concerns the gene FGFR1 and mantle cell lymphoma.